A conditional error function approach for subgroup selection in adaptive clinical trials

被引:69
作者
Friede, T. [2 ]
Parsons, N. [1 ]
Stallard, N. [1 ]
机构
[1] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England
[2] Univ Med Ctr Gottingen, Dept Med Stat, Gottingen, Germany
基金
英国医学研究理事会;
关键词
adaptive design; combination test; conditional error function; closed test procedure; subgroup selection; short-term endpoint;
D O I
10.1002/sim.5541
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Growing interest in personalised medicine and targeted therapies is leading to an increase in the importance of subgroup analyses. If it is planned to view treatment comparisons in both a predefined subgroup and the full population as co-primary analyses, it is important that the statistical analysis controls the familywise type I error rate. Spiessens and Debois (Cont. Clin. Trials, 2010, 31, 647656) recently proposed an approach specific for this setting, which incorporates an assumption about the correlation based on the known sizes of the different groups, and showed that this is more powerful than generic multiple comparisons procedures such as the Bonferroni correction. If recruitment is slow relative to the length of time taken to observe the outcome, it may be efficient to conduct an interim analysis. In this paper, we propose a new method for an adaptive clinical trial with co-primary analyses in a predefined subgroup and the full population based on the conditional error function principle. The methodology is generic in that we assume test statistics can be taken to be normally distributed rather than making any specific distributional assumptions about individual patient data. In a simulation study, we demonstrate that the new method is more powerful than previously suggested analysis strategies. Furthermore, we show how the method can be extended to situations when the selection is not based on the final but on an early outcome. We use a case study in a targeted therapy in oncology to illustrate the use of the proposed methodology with non-normal outcomes. Copyright (c) 2012 John Wiley & Sons, Ltd.
引用
收藏
页码:4309 / 4320
页数:12
相关论文
共 30 条
  • [1] Freidlin B., Simon R., Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients, Clinical Cancer Research, 11, pp. 7872-7878, (2005)
  • [2] Wang S.-J., O'Neill R.T., Hung H.M.J., Approaches to evaluation of treatment effect in randomised clinical trials with genomic subset, Pharmaceutical Statistics, 6, pp. 227-244, (2007)
  • [3] Simes R.J., An improved Bonferroni procedure for multiple test of significance, Biometrika, 73, pp. 751-754, (1986)
  • [4] Spiessens B., Debois M., Adjusted significance levels for subgroup analysis in clinical trials, Contemporary Clinical Trials, 31, pp. 647-656, (2010)
  • [5] Bauer P., Kieser M., Combining different phases in the development of medical treatments within a single trial, Statistics in Medicine, 18, pp. 1833-1848, (1999)
  • [6] Bretz F., Schmidli H., Konig F., Racine A., Maurer W., Confirmatory seamless phase II/III clinical trials with hypothesis selection at interim: general concepts, Biometrical Journal, 48, pp. 623-634, (2006)
  • [7] Stallard N., Todd S., Sequential designs for phase III clinical trials incorporating treatment selection, Statistics in Medicine, 22, pp. 689-703, (2003)
  • [8] Stallard N., Friede T., Flexible group-sequential designs for clinical trials with treatment selection, Statistics in Medicine, 27, pp. 6209-6227, (2008)
  • [9] Koenig F., Brannath W., Bretz F., Posch M., Adaptive Dunnett tests for treatment selection, Statistics in Medicine, 27, pp. 1612-1625
  • [10] Di Scala L., Glimm E., Time-to-event analysis with treatment arm selection at interim, Statistics in Medicine, 30, pp. 3067-3081, (2011)